Treatment of Primary Myelofibrosis with Anaemia and Adequate Serum Erythropoietin

This protocol addresses a specific sub-population of patients with primary myelofibrosis who present with anaemia alongside an adequate serum erythropoietin level (≥500 mU/mL) — a finding that shapes the treatment pathway chosen at this stage.

Clinical Scenario

The patient has myelofibrosis with anaemia and a serum erythropoietin level measured at ≥500 mU/mL. Serum EPO level is a key determinant here: those with levels at or above this threshold are considered to have an adequate endogenous erythropoietin response, which influences which anaemia-directed strategy is appropriate.

Treatment Approach (Summary)

In this setting, guidelines support a danazol-based approach as the initial strategy, with further options available depending on individual patient factors.

Full sequencing, combination considerations, and the complete algorithm are available in the structured protocol below.

Treatment Goal Haemoglobin response, assessed at 6 months.

Instant Access to Structured Evidence-Based Regimens

References

Serum EPO level — Adequate. However routine practice would suggest that those with EPO levels <500 mU/mL likely merit an ESA trial for 12 weeks.
Danazol, a semisynthetic androgen, can demonstrate anaemia responses in up to 30% of patients.
If tolerated, a minimum of 12 weeks of therapy is warranted to assess if there is a response.
A trial of danazol, with or without ruxolitinib, can be considered initially for a period of 6 months including in patients who have failed a trial of ESA (Grade 1C).

View source ↗